For millions of people living with high blood pressure, the standard cocktail of medications often isn’t enough. This “treatment-resistant” hypertension leaves patients in a precarious position, facing a significantly higher risk of stroke, heart attack, and kidney failure despite their best efforts to manage the condition. Now, results from a large-scale Phase III clinical trial suggest a new pharmacological path forward for those whose blood pressure remains dangerously high.
A new target for resistant hypertension
The international BaxHTN trial, led by Professor Bryan Williams of the UCL Institute of Cardiovascular Science and sponsored by AstraZeneca, tested a new tablet called baxdrostat. The study involved nearly 800 patients across 214 clinics worldwide, focusing specifically on individuals who had not seen success with existing therapies.
The results, presented at the European Society of Cardiology (ESC) Congress 2025 in Madrid and published in the New England Journal of Medicine, showed that baxdrostat can make a clinically meaningful difference. After 12 weeks, patients taking a daily dose of 1 mg or 2 mg saw their systolic blood pressure drop by approximately 9 to 10 mmHg more than those receiving a placebo.
Although a 10 mmHg drop might seem modest, in cardiovascular medicine, it is a critical threshold. This level of reduction is linked to a substantial decrease in the risk of heart failure, kidney disease, and life-threatening cardiovascular events. Notably, about 40 percent of the patients taking baxdrostat reached healthy blood pressure levels, compared to fewer than 20 percent in the placebo group.
Clinical Context: Shifting Targets
The definition of “controlled” blood pressure has become more stringent. The ESC 2024 guidelines lowered the target blood pressure to less than 130/80 mmHg, down from the previous target of 140/90 mmHg. This shift means a larger portion of the population is now classified as having uncontrolled hypertension, increasing the urgent need for more effective treatments.
Blocking the aldosterone drive
To understand why baxdrostat works where other drugs fail, it is necessary to look at the role of aldosterone. This hormone is responsible for regulating salt and water levels in the body. When the body produces too much aldosterone, it retains excess salt and water, which increases the volume of blood and drives pressure upward.
While scientists have long known that aldosterone plays a role in hypertension, targeting it effectively has been a challenge. Baxdrostat works by directly blocking the production of this hormone, addressing a primary biological driver of uncontrolled blood pressure.
According to Professor Williams, the reductions in systolic blood pressure persisted for up to 32 weeks with no unanticipated safety findings. This suggests that for a significant number of patients, aldosterone is the hidden culprit behind their resistant hypertension.
The shifting global burden of disease
The public health implications of this treatment extend far beyond the UK, where roughly 14 million people live with hypertension. Globally, the condition affects about 1.3 billion people, and nearly half of those cases remain uncontrolled.
The geography of the crisis is also shifting. Once viewed primarily as a problem for wealthier Western nations, the burden of hypertension has moved toward Eastern and lower-income countries due to changing diets and other systemic factors. More than half of all hypertension cases are now found in Asia, including 226 million people in China and 199 million in India.
Because of this global prevalence, the potential impact of a drug like baxdrostat is vast. Professor Williams noted that the medication could potentially help as many as 10 million people in the UK and up to half a billion people worldwide in reaching optimal blood pressure control.
Analytical Q&A
Who is the ideal candidate for this new treatment?
Baxdrostat is specifically designed for patients with uncontrolled or resistant hypertension—those whose blood pressure remains dangerously high despite taking multiple standard antihypertensive medications.
Is this drug available for prescription now?
The findings approach from a Phase III clinical trial. While the results are promising and have been published in a major medical journal, the drug must still move through the necessary regulatory approval processes before it becomes available for general clinical use.
How does this differ from existing blood pressure medications?
Many standard medications target different pathways, such as relaxing blood vessels or reducing fluid via the kidneys. Baxdrostat specifically blocks the production of aldosterone, the hormone that drives salt and water retention.
As medical targets for blood pressure become more ambitious, how will healthcare systems balance the need for new pharmaceuticals with the ongoing challenge of dietary salt reduction globally?





